Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Shares outstanding
Johnson & Johnson's shares outstanding at the end of fiscal 2025 was $2.4B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $2.4B. Over the past ten years it has ranged from $2.4B (fiscal 2025) to $2.8B (fiscal 2015) — the current reading is the lowest in ten years. Johnson & Johnson ranks 4th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $2.4B | 0.00% |
| FY2024 | $2.4B | (5.12%) |
| FY2023 | $2.6B | (3.89%) |
| FY2022 | $2.7B | (0.38%) |
| FY2021 | $2.7B | 0.12% |
| FY2020 | $2.7B | (0.51%) |
| FY2019 | $2.7B | (1.63%) |
| FY2018 | $2.7B | (0.60%) |
| FY2017 | $2.7B | (1.56%) |
| FY2016 | $2.8B | (0.85%) |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $2.4B | (0.21%) |
| Mar 2026 | $2.4B | 0.65% |
| Dec 2025 | $2.4B | 0.03% |
| Sep 2025 | $2.4B | 0.39% |
| 42 more quarters | Free account |
Against its own ten years
Low $2.4B
High $2.8B
Ten-year median
$2.7B
Current reading's percentile
18
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.7B |
| MRK Merck & Co., Inc. compare | $2.5B |
| JNJ Johnson & Johnson | $2.4B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. compare | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.2B |
| LLY Eli Lilly and Company compare | $893.7M |
| AMGN Amgen Inc. compare | $544.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on JNJ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement